At UC San Diego School of Medicine, researchers have developed a gene therapy that travels through the bloodstream to protect brain neurons from the toxic accumulation of TDP-43, a protein that drives frontotemporal dementia, complicates Alzheimer's disease, and underlies amyotrophic lateral sclerosis. Published in Alzheimer's & Dementia, the study offers a fresh approach to neurodegeneration: instead of trying to remove damage after it occurs, the therapy strengthens neurons' own ability to survive and function under stress.
TDP-43 may not be a familiar name outside neuroscience circles, but it has emerged as one of the most consequential proteins in age-related brain disease. When it accumulates abnormally, TDP-43 triggers the progressive cognitive decline and motor loss characteristic of ALS and frontotemporal dementia—the latter gaining public awareness following actor Bruce Willis's diagnosis in 2023. More strikingly, researchers estimate that TDP-43 is present in more than half of Alzheimer's cases, where its presence correlates with faster cognitive decline, greater brain atrophy, and worsening memory loss.
The innovation lies in how the therapy is delivered and what it does. Rather than requiring direct injections into brain tissue, researchers used a modified, harmless virus to deliver a gene called SynCav1 systemically through the bloodstream. This approach boosts production of caveolin-1, a neuroprotective protein that organizes critical signaling pathways in the brain. "Many therapies for neurodegenerative disease focus on removing toxic proteins, but neurons are also losing their ability to cope with that stress," explained Brian Head, a professor of anesthesiology at UC San Diego School of Medicine and senior author of the study. "Our findings suggest that strengthening the neuron's resilience itself may be a powerful therapeutic strategy, even when toxic proteins are already present."
When tested in mice, the results were striking. The therapy successfully crossed the blood-brain barrier and boosted caveolin-1 expression across the brain and spinal cord. Treated mice showed preserved learning, memory, and fear extinction—the ability to become less fearful of a stimulus after repeated exposure. The therapy also reduced pathological TDP-43 levels in the cortex and hippocampus, regions crucial for cognitive function, voluntary movement, and social behavior. At the cellular level, it protected mitochondria, the energy-producing structures neurons depend on, and preserved membrane lipid rafts, the subcellular structures that allow neurons to communicate with one another.
The findings offer more than just a potential treatment path. They illuminate what happens inside neurons during neurodegeneration. "We found that TDP-43 is not only accumulating in the wrong subcellular compartments, but also disrupts cellular processes that are essential for neurons to communicate with one another," said Shanshan Wang, a co-corresponding author and assistant professor of anesthesiology at UC San Diego. "SynCav1 appears to help preserve this molecular machinery and subcellular localization."
While more research is needed before this approach reaches patients, the study demonstrates a paradigm shift: building neuronal resilience may prove as important as removing toxic proteins themselves. For people at risk of frontotemporal dementia, Alzheimer's, and ALS, that reframing could open entirely new therapeutic possibilities.